Current partner codePEPTIDESDE
PeptideStat
Menu

Vendors

Compare pricesVendor directoryVendor reviewsDiscount codesLab tests & COAs

Research

ResearchDatabaseClinical trials

Tools

All calculatorsReconstitutionAccumulationUnit converterPeptide chemistry
NCT01786915·Phase 1·INTERVENTIONAL

Safety and Pharmacokinetic (PK) Study of Oral Bendavia Administered for 7 Days

ElamipretideOtherCompleted

Status

Completed

Phase

Phase 1

Enrollment

30

Locations

1

Results

Not posted

Publications

0

Study summary

What the protocol is testing.

The purpose of this study is to assess the study medication blood levels after administration of a repeat oral capsules (one capsule each day for seven days) of Bendavia at one of two dose levels. The effects of Bendavia on the volunteers will also be assessed.

Interventions

Treatment arms and agents.

DRUG

Bendavia 10mg

DRUG

Bendavia 50mg

DRUG

Placebo

Timeline

From registration to results.

  1. First posted

    Feb 8, 2013

  2. Study start

    Feb 2013

  3. Primary completion

    Mar 2013

  4. Study completion

    Mar 2013

  5. Results posted

    Not reported

  6. Registry updated

    Apr 2, 2014

Outcomes

What the study measures.

Primary outcomes

Mean peak plasma concentration (Cmax) of Bendavia (ng/ml) on Day 1 in each cohort.

Time frame · Immediately prior to dosing (Day 1, 0hr) to 24 hours post-dose

Blood drawn at pre-dose (immediately prior to study drug ingestion) and post-dose at +0.5, +1, +1.5, +2, +2.5, +3, +3.5, +4, +5, +6, +8, +12, +18 hours and pre-Day2-dose (approximately 24 hours post-Day1-dose) will be assessed for Bendavia plasma concentrations. Mean Cmax is defined as the mean of maximum concentration reported for each subject by cohort.

Mean peak plasma concentration (Cmax) of Bendavia (ng/ml) on Day 7 in each cohort.

Time frame · Immediately prior to dosing (Day 7, 0hr) to 24 hours post-dose

Blood drawn at Day 7 pre-dose (immediately prior to study drug ingestion) and post-dose at +0.5, +1, +1.5, +2, +2.5, +3, +3.5, +4, +5, +6, +8, +12, +18 and +24 hours will be assessed for Bendavia plasma concentrations. Mean Cmax is defined as the mean of maximum concentration reported for each subject by cohort.

Mean time to peak plasma concentration (Tmax) of Bendavia (hr) on Day 1 in each cohort.

Time frame · Immediately prior to dosing (Day 1, 0hr) to 24 hours post-dose

Blood drawn at Day 1 pre-dose (immediately prior to study drug ingestion) and post-dose at +0.5, +1, +1.5, +2, +2.5, +3, +3.5, +4, +5, +6, +8, +12, +18 hours and pre-Day2-dose (approximately 24 hours post-Day1-dose) will be assessed for Bendavia plasma concentrations. Mean Tmax is defined as the mean of the time of maximum concentration reported for each subject by cohort.

Mean time to peak plasma concentration (Tmax) of Bendavia (hr) on Day 7 in each cohort.

Time frame · Immediately prior to dosing (Day 7, 0hr) to 24 hours post-dose

Blood drawn at Day 7 pre-dose (immediately prior to study drug ingestion) and post-dose at +0.5, +1, +1.5, +2, +2.5, +3, +3.5, +4, +5, +6, +8, +12, +18 and +24 hours will be assessed for Bendavia plasma concentrations. Mean Tmax is defined as the mean of the time of maximum concentration reported for each subject by cohort.

Mean Area Under the Curve (AUC) from 0-24 hours on Day 1 for Bendavia (hr.ng/ml) in the time from dosing to 24 hours post-dose in each cohort.

Time frame · Immediately prior to dosing (Day 1, 0hr) to 24 hours post-dose

Blood drawn at Day 1 pre-dose (immediately prior to study drug ingestion) and post-dose at +0.5, +1, +1.5, +2, +2.5, +3, +3.5, +4, +5, +6, +8, +12 and +18 hours and pre-D2-dose (approximately 24 hours post-D1-dose) will be assessed for Bendavia plasma concentrations. AUC (0-24hr) will be calculated using validated pharmacokinetic analysis software and mean AUC for Bendavia is defined as the mean of AUC (0-24hr) reported for each subject by cohort

Mean Area Under the Curve (AUC) from 0-24 hours on Day 7 for Bendavia (hr.ng/ml) in the time from dosing to 24 hours post-dose in each cohort.

Time frame · Immediately prior to dosing (Day 1, 0hr) to 24 hours post-dose

Blood drawn at Day 7 pre-dose (immediately prior to study drug ingestion) and post-dose at +0.5, +1, +1.5, +2, +2.5, +3, +3.5, +4, +5, +6, +8, +12, +18 and +24 hours post-D7-dose will be assessed for Bendavia plasma concentrations. AUC (0-24hr) will be calculated using validated pharmacokinetic analysis software and mean AUC for Bendavia is defined as the mean of AUC (0-24hr) reported for each subject by cohort.

Ratio of AUC0-24h calculated on Day 7 to AUC0-24h calculated on Day 1 [AUC0-24h (d7)/AUC0-24h (d1)].

Time frame · Immediately prior to dosing (Day 1, 0hr) to 24 hours post-Day 7-dose

Mean AUC (0-24hr) calculated at Day 7 as the ratio of Mean AUC (0-24hr) calculated at Day 1 will be calculated for each Bendavia-treated cohort.

Number of adverse events observed with and without Bendavia

Time frame · From time of study drug administration to End of Study (Day 10)

Adverse events will be tabulated by treatment group. No statistical analysis will be performed.

Secondary outcomes

Mean change in concentration of urinary 8-isoprostane (pg/mg creatinine) from pre-dose through to study Day 10 for each cohort.

Time frame · Prior to dosing (Day 1, 0hr) to Study Day 10

Spot urine samples will be collected at pre-dose on each day of dosing (Days 1-7) and at 24, 48 and 72 hours post-Day7-dose for assay of 8-isoprostane (8-EPIPGF2a) and creatinine. Change from baseline value at each time point assessed will be calculated for each subject. Mean change from baseline is defined as the mean of the change in 8-EPIPGF2a/creatinine for each subject by cohort.

Mean change in concentration of urinary 8-hydroxy-2-deoxyguanosine (ng/mg creatinine) from pre-dose through to study Day 10 for each cohort.

Time frame · Prior to dosing (Day 1, 0hr) to Study Day 10

Spot urine samples will be collected at pre-dose on each dosing day (Days 1-7) and at 24, 48 and 72 hours post-D7-dose for assay of 8- hydroxy-2-deoxyguanosine (8-OHDG) and creatinine. Change from baseline value at each time point assessed will be calculated for each subject. Mean change from baseline is defined as the mean of the change in 8-OHDG/creatinine for each subject by cohort.

Mean Area Under the Curve (AUC0-24hr) on Day 1 for Bendavia metabolite M1 (hr.ng/ml) in the time from dosing to 24 hours post-D1-dose in each cohort.

Time frame · Immediately prior to dosing (Day 1,0hr) to 24 hours post-D1-dose

Blood drawn at Day 1 pre-dose (immediately prior to study drug ingestion) and post-dose at +0.5, +1, +1.5, +2, +2.5, +3, +3.5, +4, +5, +6, +8, +12, +18 hours and pre-Day2-dose (approximately 24 hours post-Day1-dose) will be assessed for M1 plasma concentrations. AUC (0-24) will be calculated using validated pharmacokinetic analysis software and mean AUC for Bendavia metabolite M1 is defined as the mean of AUC (0-24) reported for each subject by cohort.

Mean Area Under the Curve (AUC0-24hr) on Day 1 for Bendavia metabolite M2 (hr.ng/ml) in the time from dosing to 24 hours post-D1-dose in each cohort.

Time frame · Immediately prior to dosing (Day 1,0hr) to 24 hours post-D1-dose

Blood drawn at Day 1 pre-dose (immediately prior to study drug ingestion) and post-dose at +0.5, +1, +1.5, +2, +2.5, +3, +3.5, +4, +5, +6, +8, +12, +18 hours and pre-Day2-dose (approximately 24 hours post-Day1-dose) will be assessed for M2 plasma concentrations. AUC (0-24) will be calculated using validated pharmacokinetic analysis software and mean AUC for Bendavia metabolite M2 is defined as the mean of AUC (0-24) reported for each subject by cohort.

Mean Area Under the Curve on Day 7 (AUC0-24hr) for Bendavia metabolite M1 (hr.ng/ml) in the time from dosing to 24 hours post-D7-dose in each cohort.

Time frame · Immediately prior to dosing (Day 7,0hr) to 24 hours post-D7-dose

Blood drawn at Day 7 pre-dose (immediately prior to study drug ingestion) and post-dose at +0.5, +1, +1.5, +2, +2.5, +3, +3.5, +4, +5, +6, +8, +12, +18 and +24 hours will be assessed for M1 plasma concentrations. AUC (0-24) will be calculated using validated pharmacokinetic analysis software and mean AUC for Bendavia metabolite M1 is defined as the mean of AUC (0-24) reported for each subject by cohort.

Mean Area Under the Curve on Day 7 (AUC0-24hr) for Bendavia metabolite M2 (hr.ng/ml) in the time from dosing to 24 hours post-D7-dose in each cohort.

Time frame · Immediately prior to dosing (Day 7,0hr) to 24 hours post-D7-dose

Blood drawn at Day 7 pre-dose (immediately prior to study drug ingestion) and post-dose at +0.5, +1, +1.5, +2, +2.5, +3, +3.5, +4, +5, +6, +8, +12, +18 and +24 hours will be assessed for M2 plasma concentrations. AUC (0-24) will be calculated using validated pharmacokinetic analysis software and mean AUC for Bendavia metabolite M2 is defined as the mean of AUC (0-24) reported for each subject by cohort.

Ratio of AUC0-24h for M1 calculated on Day 7 to AUC0-24h calculated on Day 1 [AUC0-24h (d7)/AUC0-24h (d1)].

Time frame · Immediately prior to dosing (Day 1, 0hr) to 24 hours post-Day 7-dose

Mean AUC (0-24hr) for M1 calculated at Day 7 as the ratio of Mean AUC (0-24hr) for M1 calculated at Day 1 will be calculated for each Bendavia-treated cohort.

Ratio of AUC0-24h for M2 calculated on Day 7 to AUC0-24h calculated on Day 1 [AUC0-24h (d7)/AUC0-24h (d1)].

Time frame · Immediately prior to dosing (Day 1, 0hr) to 24 hours post-Day 7-dose

Mean AUC (0-24hr) for M2 calculated at Day 7 as the ratio of Mean AUC (0-24hr) for M2 calculated at Day 1 will be calculated for each Bendavia-treated cohort.

Eligibility

Who can take part.

Minimum age
18 Years
Maximum age
65 Years
Sex
ALL
Healthy volunteers
Yes

Inclusion Criteria: * Healthy adult males or females aged between 18 and 65 years of age with signed informed consent. * Women who are not post-menopausal (without menstrual bleed for \>24 months) or surgically sterile must have a negative serum pregnancy test at screening and within 24 hours of treatment with understanding (through informed consent process) to not become pregnant over the duration of the study and must agree to employ an effective form of birth control for the duration of the study. * Acceptable forms of birth control are: double-barrier contraceptives (condom, diaphragm with spermicide) or interuterine device (IUD) 1 week prior to and at least 30 days post treatment even if hormonal contraceptives are used. Exclusion Criteria: * Serum sodium level below the lower limit of the site's clinical laboratory normal range at the study qualification visit, * Clinically significant laboratory abnormalities as determined by the Principal Investigator at laboratory screening * Creatinine clearance calculated by the Cockcroft and Gault method calculated to be \<90 mL/min for males and \<80 mL/min for females * Clinically significant abnormalities on physical examination, * Body weight less than 60 kg or greater than 80 kg or a body mass index of less than 18 kg/m2 or greater than 32 kg/m2, * Any disease or condition that might compromise the cardiovascular, hematological, renal, hepatic, pulmonary (including chronic asthma), endocrine (e.g., diabetes), central nervous, or gastrointestinal (including an ulcer) systems, * History of seizures or history of epilepsy, * History of serious (Principal Investigator judgment) mental illness, * Participant in any research involving investigational product within 30 days before planned date of drug administration, * Positive serology for HIV 1, HIV 2, HBsAg, or hepatitis C virus (HCV), * Fever greater than 37.5°C at the time of planned dosing, * Suspicion, or recent history, of alcohol or substance abuse, * Donated blood or blood products within the past 30 days, * Women who are pregnant or breastfeeding, * Employee or family member of an employee of the investigational site, * Subjects who currently smoke cigarettes, cigars, pipes or chew tobacco products or who have used any tobacco product in the 30 days prior to screening, * Subjects who are either unwilling to agree to refrain from use or found to be using: * Alcohol, caffeine, xanthine-containing food or beverages, nicotine products and over-the-counter medications with the exception of Tylenol from 24 hours prior to dosing and throughout the confinement periods * Prescription medications from 14 days prior to and 7 days post treatment (excluding hormonal contraceptives) * Hormonal contraceptives without concomitant use of double-barrier contraceptives (condom, diaphragm with spermicide) for a period of 7 days prior to and 30 days post treatment * Subjects having previous exposure to Bendavia

Study locations

1 registered sites.

United States. Showing up to 24 locations stored in the fast local snapshot.

Clinical Pharmacology of Miami Inc

Miami, Florida, United States

Publications

Results and literature.

No PMID-linked publications were present in this registry snapshot.

Primary links

Continue at the source.

ClinicalTrials.gov ↗Search PubMed ↗Search FDA ↗Search EMA ↗

Related trials

More studies on Elamipretide.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.

TrialsElamipretide trial dashboard →